Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Genetics of Menkes Kinky Hair Disease Workup

  • Author: Stephen G Kaler, MD, MPH; Chief Editor: Maria Descartes, MD  more...
 
Updated: Sep 08, 2015
 

Laboratory Studies

See the list below:

  • In addition to the subtle clinical manifestations in neonates with Menkes kinky hair disease (MKHD), early diagnosis is complicated by the unreliability of the usual biochemical markers (ie, low serum copper and ceruloplasmin) during the first several weeks of life.
  • Laboratory findings in Menkes kinky hair disease include low copper and ceruloplasmin, although values for these are also low in healthy infants during the first 6 weeks of life and thus are not diagnostic for Menkes kinky hair disease during this time frame. The levels in healthy newborns overlap those of patients with Menkes kinky hair disease.
  • In contrast, plasma and cerebrospinal fluid (CSF) catechol levels are distinctively abnormal in patients with Menkes kinky hair disease at all ages, including the newborn period and even prenatally. As noted in Pathophysiology, high levels of the catechols dihydroxyphenylalanine (DOPA), dihydrophenylacetic acid, and dopamine and low level of dihydroxyphenylglycol (DHPG), the deaminated metabolite of norepinephrine (NE), are hallmarks of the partial dopamine beta-hydroxylase (DBH) deficiency invariably associated with Menkes kinky hair disease and occipital horn syndrome (OHS). This rapid and reliable plasma or CSF catechol assay is available on a research basis at NIH.
  • Copper egress in cultured fibroblasts is a time-honored method for diagnosis of Menkes kinky hair disease and OHS. Considered a definitive diagnostic test, it requires propagation of cells obtained from a skin biopsy for at least several weeks before the assay can be performed. The assay is being replaced by molecular analysis but remains useful for laboratories with experience in working with radiolabeled copper (half-life of copper Cu-64 is approximately 12 h) and in the conduct of pulse/chase experiments.
  • Because optimal success of any therapeutic strategy for this condition requires recognition of patients with Menkes kinky hair disease before the onset of neurologic symptoms, rapid tests that can reliably diagnose or exclude Menkes kinky hair disease during the neonatal period are useful.
    • One such test recently recognized is plasma catecholamine analysis (see Other Tests). Plasma catechol levels distinctively outside the reference range, indicating deficiency of DBH, have been demonstrated in a fetus as well as newborns with Menkes kinky hair disease. Sufficient data have now accrued that this assay is considered a valuable tool for rapid accurate diagnosis of Menkes kinky hair disease in the early neonatal period when interpretation of other biochemical tests is difficult.
    • The placental copper level, which is increased in Menkes kinky hair disease, represents another reliable biochemical marker for neonatal diagnosis. Rapid molecular diagnostic assays eventually may facilitate early diagnosis. Realistic consideration of newborn screening for Menkes kinky hair disease requires more predictably effective therapies than are currently available but seems theoretically possible.
  • Expression of Menkes kinky hair disease in females: Several female patients with Menkes kinky hair disease have been reported in whom chromosome rearrangement, XO/XX mosaicism, or unfavorable lyonization was responsible for expression of the full phenotype. With respect to detection of females who are carriers, clinical and biochemical parameters have not been uniformly reliable.
    • Serum copper and ceruloplasmin levels are within the reference range in carriers, as are plasma catecholamine levels (unpublished observations).
    • Copper egress in cultured cells of some obligate carriers demonstrate values within the range of males with Menkes kinky hair disease or intermediate between normal and affected, but many have values that overlap with the reference range, presumably because of lyonization and apparent selection against the mutant cell type.
    • Pili torti in the hair of the mother of a patient with Menkes kinky hair disease is considered definitive proof of her status as a gene carrier (see Other Tests).
    • As in prenatal testing, molecular diagnostic approaches aid immensely in carrier detection once a given family's mutation has been characterized in a male with Menkes kinky hair disease.
Next

Imaging Studies

The following imaging studies are often helpful in the evaluation and treatment of patients with Menkes kinky hair disease or OHS:

  • Brain MRI to assess for gross structural lesions, degree of myelination, and vascular tortuosity
    • White matter abnormalities reflecting impaired myelination, diffuse atrophy, ventriculomegaly, and tortuosity of cerebral blood vessels are typical findings on brain MRI.
    • Subdural hematomas are common in infants with Menkes kinky hair disease, and stroke can occur in patients with the disease who survive longer.
  • Magnetic resonance angiography (MRA) of the brain for closer detail of vasculopathy: The "corkscrew" appearance of cerebral vessels is well visualized by MRA, a noninvasive method for study of the vasculature.
  • Echocardiography: Dysplastic coronary vessels may be detectable by echocardiography.
  • Cystography or pelvic ultrasonography: These studies reveal diverticula of the urinary bladder in nearly every patient with Menkes kinky hair disease.
  • Abdominal ultrasonography: This study is used to assess for antral polyps (a rare clinical problem in Menkes kinky hair disease).
  • Radiography: These images often disclose abnormalities of bone formation in the skull (wormian bones), long bones (metaphyseal spurring), and ribs (anterior flaring, multiple fractures).
Previous
Next

Other Tests

See the list below:

  • Placental copper level: In pregnancies at risk for Menkes kinky hair disease, determination of the placental copper level is a reliable and fairly rapid diagnostic test in the newborn period. According to Centano of the US Armed Forces Institute of Pathology (personal communication), placental copper is 3-fold to 5-fold elevated in pregnancies affected by Menkes kinky hair disease relative to healthy controls.
  • Pili torti on light microscopic examination of hair
    • Pili torti on light microscopic examination of hair is another reliable diagnostic test. However, as with plasma copper and ceruloplasmin, this sign is not useful for very early diagnosis (ie, prior to neurologic symptoms) because the hair in individuals with Menkes kinky hair disease is often normal from birth until several months of age.
    • Pili torti in the hair of the mother of a patient with Menkes kinky hair disease is considered definitive proof of her status as a gene carrier. However, this hair abnormality is detectable in only approximately one half of obligate Menkes heterozygotes. Thus, even if microscopic examination of hair from a potential female heterozygote is negative for pili torti, the carrier state cannot be ruled out.
  • Molecular analysis: Molecular analysis of the Menkes/OHS gene has been approached in several ways. The author favors a multiplex polymerase chain reaction (PCR) assay to screen for deletions, followed by heteroduplex analysis (either D-HPLC or manual) with DNA sequencing used to confirm abnormalities. The author sequences the entire coding region and intron-exon junctions if screening approaches do not suggest the location of mutation within 1 of the 23 exons that comprise the coding sequence of the gene. To date, the author has found mutations in more than 94% of NIH-protocol patients.
  • Electroencephalograms: EEGs are used routinely to investigate possible seizure activity. EEG findings are usually moderately to severely abnormal, although normal tracings have been recorded in some individuals with classic Menkes kinky hair disease.
Previous
Next

Procedures

Lumbar puncture (ie, spinal tap) to examine the CSF is almost always performed in the early evaluation of infants manifesting neurodevelopmental symptoms.

Skin biopsy procedure to establish fibroblast cultures as a source of patient RNA and DNA or to perform diagnostic studies (eg, copper transport assays) may be requested for infants suspected of having Menkes kinky hair disease.

Previous
Next

Histologic Findings

Pathology of the brain in Menkes kinky hair disease includes marked neuronal cell loss in the cerebral cortex and cerebellum, severe demyelination, dystrophic Purkinje cells, mitochondrial proliferation, and vascular dilatation within the brain and spinal cord. Abnormal brain lipid composition, presumably reflecting impaired myelination, has been documented.

Pathologic changes of the vasculature (tortuosity and ectasia) are prominent in Menkes kinky hair disease. Defective elastin fibers have been demonstrated within the internal elastic lamina, tunica media, and intimal layers of arteries and arterioles.

Previous
 
 
Contributor Information and Disclosures
Author

Stephen G Kaler, MD, MPH Head, Unit On Pediatric Genetics, Laboratory of Clinical Genomics and Clinical Director, Intramural Research Program, National Institute of Child Health & Human Development (NICHD), National Institutes of Health

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Margaret M McGovern, MD, PhD Professor and Chair of Pediatrics, Stony Brook University School of Medicine

Margaret M McGovern, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Society of Human Genetics

Disclosure: Nothing to disclose.

Chief Editor

Maria Descartes, MD Professor, Department of Human Genetics and Department of Pediatrics, University of Alabama at Birmingham School of Medicine

Maria Descartes, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics and Genomics, American Medical Association, American Society of Human Genetics, Society for Inherited Metabolic Disorders, International Skeletal Dysplasia Society, Southeastern Regional Genetics Group

Disclosure: Nothing to disclose.

Additional Contributors

Christian J Renner, MD Consulting Staff, Department of Pediatrics, University Hospital for Children and Adolescents, Erlangen, Germany

Disclosure: Nothing to disclose.

Acknowledgements

I thank deeply the patients and families who have participated in our clinical trials and the members of my Section for their hard work and dedication to the aims of our laboratory.

References
  1. Møller LB, Hicks JD, Holmes CS, Goldstein DS, Brendl C, Huppke P, et al. Diagnosis of copper transport disorders. Curr Protoc Hum Genet. 2011 Jul. Chapter 17:Unit17.9. [Medline]. [Full Text].

  2. Kim YH, Lee R, Yoo HW, Yum MS, Bae SH, Chung SC, et al. Identification of a novel mutation in the ATP7A gene in a Korean patient with Menkes disease. J Korean Med Sci. 2011 Jul. 26(7):951-3. [Medline]. [Full Text].

  3. Datta AK, Ghosh T, Nayak K, Ghosh M. Menkes kinky hair disease: A case report. Cases J. 2008 Sep 18. 1(1):158. [Medline].

  4. Aldecoa V, Escofet-Soteras C, Artuch R, Ormazabal A, Gabau-Vila E, Martin-Martinez C. [Menkes disease: its clinical, biochemical and molecular diagnosis]. Rev Neurol. 2008 Apr 1-15. 46(7):446-7. [Medline].

  5. Danks DM, Campbell PE, Walker-Smith J, et al. Menkes' kinky-hair syndrome. Lancet. 1972 May 20. 1(7760):1100-2. [Medline].

  6. Danks DM, Cartwright E, Stevens BJ, Townley RR. Menkes' kinky hair disease: further definition of the defect in copper transport. Science. 1973 Mar 16. 179(78):1140-2. [Medline].

  7. Menkes JHM, Alter M, Steigleder GK. A sex-linked recessive disorder with retardation of growth, peculiar hair and focal cerebellar degeneration. Pediatrics. 1962. 29:764-769.

  8. Chelly J, Tumer Z, Tonnesen T, et al. Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein. Nat Genet. 1993 Jan. 3(1):14-9. [Medline].

  9. Baerlocher K, Nadal D. [Menkes syndrome]. Ergeb Inn Med Kinderheilkd. 1988. 57:77-144. [Medline].

  10. Kaler SG. Menkes disease. Adv Pediatr. 1994. 41:263-304. [Medline].

  11. Kaler SG, Tang J, Donsante A, Kaneski CR. Translational read-through of a nonsense mutation in ATP7A impacts treatment outcome in Menkes disease. Ann Neurol. 2009 Jan. 65(1):108-13. [Medline].

  12. Donsante A, Yi L, Zerfas PM, Brinster LR, Sullivan P, Goldstein DS, et al. ATP7A gene addition to the choroid plexus results in long-term rescue of the lethal copper transport defect in a Menkes disease mouse model. Mol Ther. 2011 Dec. 19(12):2114-23. [Medline]. [Full Text].

  13. Sato R, Okutani K, Higashi T, Satou M, Fujimoto K, Okazaki K. [Case report : respiratory care for anesthesia in a patient with Menkes syndrome and micrognathia]. Masui. 2009 Jan. 58(1):103-5. [Medline].

  14. Passariello M, Almenrader N, Pietropaoli P. Anesthesia for a child with Menkes disease. Paediatr Anaesth. 2008 Dec. 18(12):1225-6. [Medline].

  15. Yamashita J, Yamakage M, Kawana S, Namiki A. Two cases of Menkes disease: airway management and dental fragility. Anaesth Intensive Care. 2009 Mar. 37(2):332-3. [Medline].

  16. [Guideline] Cunniff C. Prenatal screening and diagnosis for pediatricians. Pediatrics. 2004 Sep. 114(3):889-94. [Medline].

  17. Amaravadi R, Glerum DM, Tzagoloff A. Isolation of a cDNA encoding the human homolog of COX17, a yeast gene essential for mitochondrial copper recruitment. Hum Genet. 1997 Mar. 99(3):329-33. [Medline].

  18. Bennetts HW, Chapman FE. Copper deficiency in sheep in Western Australia: a preliminary account of the aetiology of enzootic ataxia of lambs and an anemia of ewes. Aust Vet J. 1937. 13:138-49.

  19. Camakaris J, Voskoboinik I, Mercer JF. Molecular mechanisms of copper homeostasis. Biochem Biophys Res Commun. 1999 Aug 2. 261(2):225-32. [Medline].

  20. Francis MJ, Jones EE, Levy ER, et al. A Golgi localization signal identified in the Menkes recombinant protein. Hum Mol Genet. 1998 Aug. 7(8):1245-52. [Medline].

  21. Grange DK, Kaler SG, Albers GM, et al. Severe bilateral panlobular emphysema and pulmonary arterial hypoplasia: unusual manifestations of Menkes disease. Am J Med Genet A. 2005 Dec 1. 139(2):151-5. [Medline].

  22. Guitet M, Campistol J, Medina M. [Menkes disease: experience in copper salts therapy]. Rev Neurol. 1999 Jul 16-31. 29(2):127-30. [Medline].

  23. Kaler SG. ATP7A-related copper transport diseases-emerging concepts and future trends. Nat Rev Neurol. 2011 Jan. 7(1):15-29. [Medline].

  24. Kaler SG. Diagnosis and therapy of Menkes syndrome, a genetic form of copper deficiency. Am J Clin Nutr. 1998 May. 67(5 Suppl):1029S-1034S. [Medline].

  25. Kaler SG. Menkes disease mutations and response to early copper histidine treatment. Nat Genet. 1996 May. 13(1):21-2. [Medline].

  26. Kaler SG. Metabolic and molecular bases of Menkes disease and occipital horn syndrome. Pediatr Dev Pathol. 1998 Jan-Feb. 1(1):85-98. [Medline].

  27. Kaler SG, Buist NR, Holmes CS, et al. Early copper therapy in classic Menkes disease patients with a novel splicing mutation. Ann Neurol. 1995 Dec. 38(6):921-8. [Medline].

  28. Kaler SG, Das S, Levinson B, et al. Successful early copper therapy in menkes disease associated with a mutant transcript containing a small In-frame deletion. Biochem Mol Med. 1996 Feb. 57(1):37-46. [Medline].

  29. Kaler SG, Gahl WA, Berry SA, et al. Predictive value of plasma catecholamine levels in neonatal detection of Menkes disease. J Inherit Metab Dis. 1993. 16(5):907-8. [Medline].

  30. Kaler SG, Gallo LK, Proud VK, et al. Occipital horn syndrome and a mild Menkes phenotype associated with splice site mutations at the MNK locus. Nat Genet. 1994 Oct. 8(2):195-202. [Medline].

  31. Kaler SG, Goldstein DS, Holmes C, et al. Plasma and cerebrospinal fluid neurochemical pattern in Menkes disease. Ann Neurol. 1993 Feb. 33(2):171-5. [Medline].

  32. Kaler SG, Holmes CS, Goldstein DS, Tang J, Godwin SC, Donsante A, et al. Neonatal diagnosis and treatment of Menkes disease. N Engl J Med. 2008 Feb 7. 358(6):605-14. [Medline]. [Full Text].

  33. Kaler SG, Schwartz JP. Expression of the Menkes disease homolog in rodent neuroglial cells. Neurosci Res Commun. 1998. 23:61-66.

  34. Kaler SG, Tumer Z. Prenatal diagnosis of Menkes disease. Prenat Diagn. 1998 Mar. 18(3):287-9. [Medline].

  35. Klomp LW, Lin SJ, Yuan DS et al. Identification and functional expression of HAH1, a novel human gene involved in copper homeostasis. J Biol Chem. 1997 Apr 4. 272(14):9221-6. [Medline].

  36. Kodama H, Murata Y, Kobayashi M. Clinical manifestations and treatment of Menkes disease and its variants. Pediatr Int. 1999 Aug. 41(4):423-9. [Medline].

  37. La Fontaine SL, Firth SD, Camakaris J, et al. Correction of the copper transport defect of Menkes patient fibroblasts by expression of the Menkes and Wilson ATPases. J Biol Chem. 1998 Nov 20. 273(47):31375-80. [Medline].

  38. Levinson B, Conant R, Schnur R, et al. A repeated element in the regulatory region of the MNK gene and its deletion in a patient with occipital horn syndrome. Hum Mol Genet. 1996 Nov. 5(11):1737-42. [Medline].

  39. Mercer JF, Livingston J, Hall B, et al. Isolation of a partial candidate gene for Menkes disease by positional cloning. Nat Genet. 1993 Jan. 3(1):20-5. [Medline].

  40. Moller LB, Tumer Z, Lund C, et al. Similar splice-site mutations of the ATP7A gene lead to different phenotypes: classical Menkes disease or occipital horn syndrome. Am J Hum Genet. 2000 Apr. 66(4):1211-20. [Medline].

  41. Payne AS, Gitlin JD. Functional expression of the menkes disease protein reveals common biochemical mechanisms among the copper-transporting P-type ATPases. J Biol Chem. 1998 Feb 6. 273(6):3765-70. [Medline].

  42. Petris MJ, Mercer JF. The Menkes protein (ATP7A; MNK) cycles via the plasma membrane both in basal and elevated extracellular copper using a C-terminal di-leucine endocytic signal. Hum Mol Genet. 1999 Oct. 8(11):2107-15. [Medline].

  43. Petris MJ, Mercer JF, Camakaris J. The cell biology of the Menkes disease protein. Adv Exp Med Biol. 1999. 448:53-66. [Medline].

  44. Petris MJ, Strausak D, Mercer JF. The Menkes copper transporter is required for the activation of tyrosinase. Hum Mol Genet. 2000 Nov 22. 9(19):2845-51. [Medline].

  45. Prohaska JR, Tamura T, Percy AK, Turnlund JR. In vitro copper stimulation of plasma peptidylglycine alpha-amidating monooxygenase in Menkes disease variant with occipital horns. Pediatr Res. 1997 Dec. 42(6):862-5. [Medline].

  46. Pufahl RA, Singer CP, Peariso KL, et al. Metal ion chaperone function of the soluble Cu(I) receptor Atx1. Science. 1997 Oct 31. 278(5339):853-6. [Medline].

  47. Robertson D, Goldberg MR, Onrot J, et al. Isolated failure of autonomic noradrenergic neurotransmission. Evidence for impaired beta-hydroxylation of dopamine. N Engl J Med. 1986 Jun 5. 314(23):1494-7. [Medline].

  48. Sarkar B, Lingertat-Walsh K, Clarke JT. Copper-histidine therapy for Menkes disease. J Pediatr. 1993 Nov. 123(5):828-30. [Medline].

  49. Schaefer M, Gitlin JD. Genetic disorders of membrane transport. IV. Wilson's disease and Menkes disease. Am J Physiol. 1999 Feb. 276(2 Pt 1):G311-4. [Medline].

  50. Sheela SR, Latha M, Liu P, et al. Copper-replacement treatment for symptomatic Menkes disease: ethical considerations. Clin Genet. 2005 Sep. 68(3):278-83. [Medline].

  51. Suzuki M, Gitlin JD. Intracellular localization of the Menkes and Wilson's disease proteins and their role in intracellular copper transport. Pediatr Int. 1999 Aug. 41(4):436-42. [Medline].

  52. Tumer Z, Horn N, Tonnesen T, et al. Early copper-histidine treatment for Menkes disease. Nat Genet. 1996 Jan. 12(1):11-3. [Medline].

  53. Tumer Z, Lund C, Tolshave J, et al. Identification of point mutations in 41 unrelated patients affected with Menkes disease. Am J Hum Genet. 1997 Jan. 60(1):63-71. [Medline].

  54. Tumer Z, Moller LB, Horn N. Mutation spectrum of ATP7A, the gene defective in Menkes disease. Adv Exp Med Biol. 1999. 448:83-95. [Medline].

  55. Valentine JS, Gralla EB. Delivering copper inside yeast and human cells. Science. 1997 Oct 31. 278(5339):817-8. [Medline].

  56. Voskoboinik I, Strausak D, Greenough M, et al. Functional analysis of the N-terminal CXXC metal-binding motifs in the human menkes copper-transporting P-type ATPase expressed in cultured mammalian cells. J Biol Chem. 1999 Jul 30. 274(31):22008-12. [Medline].

  57. Vulpe C, Levinson B, Whitney S, et al. Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. Nat Genet. 1993 Jan. 3(1):7-13. [Medline].

Previous
Next
 
Classic Menkes kinky hair disease in an 8-month-old male infant. Note the abnormal hair, eyelid ptosis, and jowly facial appearance.
Adolescent patient with typical occipital horn syndrome. Note elbow dislocations and genu valgum. Radiographs exhibited bilateral occipital exostoses of the skull and club-shaped distal clavicles.
Successfully treated classic Menkes kinky hair disease. Diagnosis at birth enabled copper therapy to begin when the infant was aged 8 days. The child walked independently when aged 14 months. This patient's mutation (IVS8,AS,dup5) was associated with a transcript harboring a small in-frame deletion, potentially encoding a functional copper adenosine triphosphatase (ATPase).
Menkes kinky hair disease copper adenosine triphosphatase (see text for detailed discussion).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.